Mushroom Antioxidant Ergothioneine Fights Hair Graying and Loss via SIRT1/Nrf2
Ergothioneine, found in edible fungi, activates SIRT1/Nrf2 signaling in hair follicle cells to reduce oxidative damage and reverse aging-related hair loss.
Summary
Researchers investigated ergothioneine (EGT), a potent antioxidant found in edible mushrooms, as a potential treatment for age-related hair graying and loss. Using dermal papilla cell co-culture systems, hair follicle organ cultures, aged mice, and hydrogen peroxide-induced gray hair mouse models, they found EGT activates the SIRT1/Nrf2 antioxidant pathway. This reduced inflammatory cytokines, boosted melanin-promoting factors, increased tyrosinase activity, and enhanced hair follicle cell proliferation. Both in vitro and in vivo results confirmed EGT's ability to preserve pigmentation and reduce hair loss, suggesting a promising natural compound for addressing hair aging at the molecular level.
Detailed Summary
Hair graying and hair loss are among the most visible signs of human aging, and oxidative stress is a key driver of both processes. As reactive oxygen species accumulate in hair follicles over time, they damage dermal papilla cells (DPCs) — the critical signaling hub that regulates follicle cycling and melanocyte function. Finding safe, effective antioxidants that can intervene in this process is an active area of longevity-adjacent research.
This study focused on ergothioneine (EGT), a naturally occurring amino acid antioxidant produced by edible fungi and certain bacteria. Researchers at Southern Medical University tested EGT across multiple experimental platforms: H2O2-stressed DPC cultures, co-culture systems with melanocyte (A-375) and keratinocyte (HaCaT) cell lines, ex vivo hair follicle organ cultures, aged mice, and an H2O2-induced gray hair mouse model.
Key findings showed that EGT protected DPCs from oxidative damage by activating the SIRT1/Nrf2 signaling pathway. This activation reduced secretion of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) while increasing production of pigmentation-promoting paracrine factors SCF and SDF1. In co-culture experiments, EGT-conditioned DPC secretions boosted melanin synthesis, tyrosinase activity, and melanin gene expression in A-375 cells, while promoting keratinocyte proliferation markers K19 and K14 in HaCaT cells. Animal studies confirmed reduced pigmentation dysfunction and hair loss in both aging and oxidative stress models.
These results position EGT as a multi-target intervention capable of protecting follicle integrity, preserving melanocyte function, and supporting keratinocyte renewal simultaneously — all through a single upstream pathway.
Important caveats apply: this is preclinical research only, mouse hair follicle biology differs meaningfully from human, and the specific dosing, bioavailability, and delivery mechanisms for topical or systemic EGT in humans remain to be established in clinical trials.
Key Findings
- EGT activated SIRT1/Nrf2 in dermal papilla cells, reducing IL-6, IL-1β, and TNF-α under oxidative stress.
- EGT increased SCF and SDF1 secretion from DPCs, promoting melanocyte pigmentation activity in co-culture.
- Tyrosinase activity and melanin content rose significantly in melanocytes exposed to EGT-treated DPC paracrine signals.
- In vivo, EGT reduced hair loss and gray hair progression in both aged and H2O2-treated mice.
- Hair follicle organ cultures showed EGT promoted hair shaft growth and pigmentation partly via SIRT1/Nrf2.
Methodology
Study used a multi-model design including H2O2-stressed dermal papilla cell cultures, A-375/HaCaT co-culture systems, ex vivo hair follicle organ cultures, naturally aged mice, and H2O2-induced gray hair mouse models. SIRT1/Nrf2 pathway involvement was assessed via gene and protein expression analysis alongside functional assays for melanin and inflammatory markers. Both in vitro mechanistic and in vivo phenotypic endpoints were evaluated.
Study Limitations
All findings are preclinical — mouse models and cell lines do not fully replicate human hair follicle biology or aging dynamics. The specific EGT doses, optimal delivery route, and scalable bioavailability in human scalp tissue have not been established. Mechanistic claims rely partly on co-culture paracrine inference rather than direct in vivo pathway confirmation in humans.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.